DRKS00033126招募中Unknown
Investigation of fludarabine exposure in relation to individual renal function in patients with allogeneic hematopoietic stem cell transplantation and patients with CART cell therapy
niversitätsklinikum Hamburg-Eppendorf0 个研究点目标入组 50 人开始时间: 2023年12月4日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Adult, hospitalized patients of the Clinic and Polyclinic for Stem Cell Transplantation of the UKE who receive an allogeneic hematopoietic stem cell transplantation or CART cell therapy according to indication and whose therapy plan includes fludarabine
- •Written informed consent of the patient
排除标准
- •Age < 18 years
- •Absence of written informed consent of the patient
研究者
相似试验
进行中（未招募）
1 期
Cumulative exposure to Fludarabine in patients undergoing reduced intensity allogeneic stem cell transplantation in BelgiumCTIS2023-503723-26-00niversitair Ziekenhuis Gent50
招募中
Unknown
Investigations into the influence of fludarabine exposure on the outcomeof patients after CAR-T cell therapyC90C83Multiple myeloma and malignant plasma cell neoplasmsNon-follicular lymphomaDRKS00033974niversitätsklinikum Hamburg Eppendorf200
进行中（未招募）
不适用
A phase II study in patients with fludarabine refractory CLL: Dasatinib treatment combination for Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL) - D’accord studyEUCTR2008-002236-15-NLAcademic Medical Center
已完成
3 期
GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the ElderlyAcute Myeloid LeukemiaNCT00925873French Innovative Leukemia Organisation303
招募中
不适用
Individualized dosing of fludarabine during innate allo SCT: A randomized phase II studyHematological malignancies, Allogeneic stem cell transplantation, personalized dosing of fludarabineNL-OMON24753niversity Medical Center Utrecht (UMCU)98